Nothing to see here.
Joined August 2017
- Tweets1.8K
- Following387
- Followers777
- Likes1.7K
Cointastic retweeted
🚨 Big news: our technology partner 01 Quantum Inc (@01quantuminc). just announced a Quantum-Resistant Layer 1 Migration Toolkit built with qLABS.
This toolkit is designed to help existing blockchains transition to post-quantum cryptography with a phased approach—starting with immediate asset protection via Quantum-Sig, then moving toward full chain-level migration.
Also confirmed: $qONE issuance on Hyperliquid on Feb 6, 2026, with the toolkit targeted for release by end of March 2026.
Read the announcement on The Quantum Insider 👇
Cointastic retweeted
When one of Wall Street’s most respected financial strategists removes Bitcoin from his recommended portfolio citing quantum computing threats, it’s time for the cryptocurrency industry to stop hitting the snooze button.
blogs.groupware.org.uk/01-Qu…
Cointastic retweeted
An incredibly inspiring conference between scientists, patients, and our governments... to address the health challenges of our times. The conference recordings will be released daily this coming week @latimesstudios_ and I will provide context daily till its all released on each segment
oncodaily.com/oncolibrary/us…
Cointastic retweeted
I bought $IBRX because it's solving the biggest problem humanity has ever faced.
1. The spike protein is everywhere + is weakening immune systems worldwide.
2. $IBRX Anktiva is the perfect solution and is hard to replicate.
3. It's led by @DrPatrick, with a top 1% track record.
Cointastic retweeted
$IBRX
Please read this post from Bert Dohmen, a longtime business partner of @DrPatrick
Two points in his post caught my attention:
1 - is Honolulu using Anktiva more generously than other places in The US? Or what is special about Honolulu? Does anybody know?
2 - he clearly states that Big Pharma has pushed back on Anktiva for many years. Which resulted in many unnecessary deaths.
THE TIME OF $IBRX HAS COME. WE ARE IN THE EARLY STAGE OF A REVOLUTION IN MEDICINE.
To the US FDA: lead, follow, or get out of the way.
A cure for cancer? AFter 60 years, Dr. Patrick Soon-Shiong of California may have achieved it. I have invested in his work since 2018, via his firm NANTKWEST, which went private in 2021.
His new firm, IMMUNITY BIO (IBRX) is now continuing. The AKTIVA BioShield is already approved for
Bladder cancer. When will the FDA approve it for all cancers, Dr Patrick asks.
I hope it will be soon. Billions of people around the world would benefit. The UH Cancer Center in Honolulu is already working with the technology.
My father died of prostate cancer about 40 years ago which got me interested. We found a way to cure Stage 4 cancer tumors of a family member after chemo almost killed her.
The battle continues. If Big Pharma got out of the way, millions of people could have been saved.
But the motto is, "It is more profitable to maintain than to cure."
Cointastic retweeted
$IBRX -Option Chain screenshot explains why the stock stopped exactly where it did. The $7.50 "Kill Zone": 1-See the huge teal bubble at $7.50? That represents massive Call Volume. 2-The Game: Market Makers sold those calls to retail traders. If the stock closed at $7.60 today, MMs would lose millions. 3-The Move: MMs shorted the stock to pin it below $7.50 causing those calls to expire worthless. This explains the "invisible hand" smacking the price down every time it touched $7.50. 4-Bullish Sentiment (PCR 0.64): Put/Call Ratio (Vol): 0.64. 5- Meaning: For every 10 puts bought, traders bought 16 calls. Even on a red day, the flow is aggressively bullish. People are buying the dip. Final Analysis: Today was a "clean-up" operation by Market Makers to kill options. The structural squeeze (37% SI) is untouched. You are holding a coiled spring
Cointastic retweeted
2026 is a decade since I filed this patent on June 2016. The NANT Cancer Vaccine (The Cancer BioShield Platform) is now in full scale development at @ImmunityBio. Finally, the drive to memory NK and T cells for long-term survival is being proven. This figure is another representation of the drawing in 2016 of my mind map since 1990. Reversing lymphopenia matters
ALT US20200171137A1
Cointastic retweeted
$IBRX announced that “median overall survival not yet reached and lymphopenia reversed in recurrent glioblastoma patients receiving Anktiva.”
Now, “median survival rate not yet reached” may sound like a bad headline, but in the scientist world with regard to drug testing and trials, it’s an INCREDIBLY GOOD headline.
You cannot determine a "median time of death" if the vast majority of people haven't died. The data is "not reached" because the patients are outliving the statistical model's timeline.
This means Anktiva plus CAR-NK has kept patients alive significantly longer than that historical window, which is why the endpoint hasn't been triggered.
Cointastic retweeted
$IBRX - Gemini News Analysis
The News: ImmunityBio tested a new drug combo on patients with a very deadly brain cancer.
The Result: Most of the patients are living longer than expected, and their immune systems are getting stronger, not weaker.
Rating: Overwhelmingly bullish
ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent @AmericanCancer data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more: ir.immunitybio.com/news-rele…
🚨 $IBRX just dropped🔥news: Median OS NOT YET REACHED in recurrent GBM trial with ANKTIVA + CAR-NK chemo-free combo! 19/23 patients alive, lymphopenia reversed fast, safe profile. Pipeline exploding beyond bladder— this immunotherapy beast keeps winning!💪🧠#CancerBreakthrough #IBRX
ir.immunitybio.com/news-rele…
This is actually really good^^ @DrPatrick hats off, you are actually changing the medical world!
"These Phase 2 data reflect outcomes in a second- and third-line glioblastoma population where immune collapse after standard therapy is common and options are limited. With 19 of 23 enrolled patients alive and median overall survival not yet reached, the survival profile warrants continued follow up"
"It has been extensively reported that patients with glioblastoma and lymphopenia have a significant decreased survival."
Cointastic retweeted
ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent @AmericanCancer data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more: ir.immunitybio.com/news-rele…
Cointastic retweeted
$IBRX | BTIG maintains a Buy rating on ImmunityBio and raises the price target to $9.00 from $6.00. Shares rise 6.07%.
Cointastic retweeted
I bought $IBRX because it's solving the biggest problem humanity has ever faced.
1. The spike protein is everywhere + is weakening immune systems worldwide.
2. $IBRX Anktiva is the perfect solution and is hard to replicate.
3. It's led by @DrPatrick, with a top 1% track record.
Cointastic retweeted
$IBRX Someone SOLD 5000 of the March 9 Strike PUTS and took in $1,570,000 Cash and then Bought 5000 of the March 9 Calls for $525,000. If stock closes at 9 the trade nets 1,045,000...BUT if stock flys to say 15 the 525K Investment is worth $3,000,000 and an epic squeeze would net this trader huge return. No one risks $1M on a 7 dollar stock without good information...Short Squeeze appears imminent
And another one! BTIG upgrades their target for $IBRX to 9 USD 🚀
The next broker updates their targets on @ImmunityBio
de.investing.com/news/analys…
